The most notable advances pertaining to infections in organ transplant recipients within the past year have been in the area of viral infections. Demonstration of the efficacy of oral ganciclovir for cytomegalovirus infection prophylaxis, and the promising role played by the nucleoside analogues in hepatitis B virus infection represent significant advances in these fields. Of grave concern, however, are reports of emerging resistance to lamivudine in hepatitis B. Therapeutic options for hepatitis C virus hepatitis in transplant recipients remain largely unsatisfactory. A large number of reports published last year on fungal infections in organ transplant recipients reflect the profound impact and substantial morbidity that continues to be observed with such infections, particularly invasive aspergillosis. The effective prophylaxis and therapy of invasive aspergillosis still presents a challenge.
© Lippincott-Raven Publishers.